HAS considers that the mRESVIA vaccine can be used, in the same way as other RSV vaccines, as part of the current vaccination strategy against RSV infections in adults, namely in people aged 75 and over. older and in people aged 65 and over with chronic respiratory pathologies (particularly COPD) or cardiac pathologies (particularly heart failure) likely to decompensate during an RSV infection.
The HAS does not comment, at this stage, on the relevance and necessity of repeat vaccination after the primary vaccination.
In order to simplify the vaccination process, HAS considers that the mRESVIA vaccine can be administered concomitantly with the flu and Covid-19 vaccines.
Furthermore, HAS emphasizes the importance of quickly conducting studies 1) to evaluate the effectiveness and real-life impact of the mRESVIA vaccine on hospitalizations due to RSV, 2) to evaluate the effectiveness of the mRESVIA vaccine in people aged 80 and over and in immunocompromised people, and 3) to document the effectiveness and safety of the administration of iterative boosters, in particular according to the time since the previous injection and the type of RSV vaccine previously administered.
- Recommendation
- Europe
- France
- Older adults
- RSV (Respiratory syncytial virus)
